Beam Therapeutics (BEAM) AI Stock Analysis

• Market Cap: $1.78B
• Dividend Yield: N/A
• Average Volume (3M): 2.42M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.32
• Revenue Growth: -82.90%
• EPS Growth: -155.64%
• Country: US
• Employees: 393
• Sector: Healthcare
• Sector Strength: 38
• Industry: Biotechnology
• EPS (TTM): -1.00
• Shares Outstanding: 101,162,025
• 10 Day Avg. Volume: 2,269,618
• 30 Day Avg. Volume: 2,423,402
• PEG Ratio: -0.03
• Price to Book (P/B): 2.78
• Price to Sales (P/S): 32.14
• P/FCF Ratio: -5.73
• Enterprise Value/Market Cap: 0.41
• Enterprise Value/Revenue: 14.27
• Enterprise Value/Gross Profit: -1.05K
• Enterprise Value/Ebitda: -1.76
• 1Y Price Target: $40.92
• Price Target Upside: 132.24% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 14

• Rating: 50 Neutral
• Price Target: $20.00 ▲(13.51% Upside)

Beam Therapeutics faces significant financial challenges with ongoing losses and negative cash flow, weighing heavily on the stock's overall score. The technical analysis indicates some medium-term strength, while the valuation reflects typical biotech sector challenges with unprofitability. However, the strategic acquisition of a life sciences firm offers potential growth opportunities and is viewed positively, providing a counterbalance to the financial difficulties.

Positive Factors

Efficacy and Safety

Beam's EHA update showed data from 17 Sickle Cell Disease patients with up to 15-month follow-up, demonstrating best-in-class efficacy and safety of BEAM-101, with no additional safety concerns cited.

Financial Health

The company has approximately $1.15 billion in cash and marketable securities, with an expected cash runway into 2028, suggesting strong financial health and operational longevity.

Valuation and Market Potential

BEAM-302 in AATD is expected to contribute approximately $13 per share, indicating significant potential value and investor interest due to the larger market opportunity.

Negative Factors

Data Timing

Despite the positive safety and efficacy updates, there is a modest negative impact from the delay in data timing, affecting immediate investor sentiment.

Regulatory and Timing Delays

Pushing data to 2026 delays a near-term catalyst, which could be seen as a setback for investors looking for immediate developments.

Beam Therapeutics Business Overview & Revenue Model

Company Description

Beam Therapeutics (BEAM) is a biotechnology company focused on pioneering the use of base editing to develop precision genetic medicines. The company operates within the healthcare and biotechnology sectors, aiming to create transformative therapies across a range of serious diseases, with core products centered around its proprietary base editing technology. This technology enables precise, predictable, and efficient single-base changes at targeted genomic sites, offering potential treatment options for genetic disorders, cancer, and other serious conditions.

How the Company Makes Money

Beam Therapeutics generates revenue through strategic collaborations, licensing agreements, and development milestones with other pharmaceutical companies. The company leverages its proprietary base editing platform to enter into partnerships where it grants rights to use its technology for developing specific therapies. Beam may receive upfront payments, milestone payments based on the achievement of certain development stages, and potential royalties on sales of any successfully commercialized products. Additionally, Beam invests in its internal pipeline of therapeutic candidates, which, upon successful clinical development and regulatory approval, could yield revenue from product sales. Significant partnerships with established pharmaceutical firms also contribute to its financial growth, providing both financial support and technological validation.

Beam Therapeutics Financial Statement Overview

Summary

Beam Therapeutics is experiencing significant financial challenges typical of early-stage biotech firms. The company has ongoing losses due to high R&D and operational costs. Despite a healthy gross profit margin, the net profit margin is deeply negative, reflecting difficulties in scaling operations profitably. The balance sheet shows manageable debt levels but negative return on equity due to consistent net losses. Cash flow is negative, indicating increasing cash consumption without corresponding revenue growth.

Income Statement

Beam Therapeutics shows significant challenges in profitability, with consistent negative net income and EBIT over recent periods. The gross profit margin is relatively healthy, indicating some cost control, but the net profit margin remains deeply negative due to high operating expenses. Revenue growth is stagnant, especially compared to the larger increases in operating losses, indicating a struggle to scale operations profitably.

Balance Sheet

The company's balance sheet reflects moderate leverage with a debt-to-equity ratio that suggests manageable debt levels relative to equity. However, the return on equity is negative due to consistent net losses, indicating that shareholders' equity is not generating positive returns. The equity ratio indicates a stable capital structure, with a significant portion of assets funded by equity, which is a positive aspect amidst financial struggles.

Cash Flow

Beam Therapeutics has negative free cash flow, reflecting ongoing operational cash burn. The operating cash flow to net income ratio indicates that cash flow is less negative than net income, suggesting non-cash expenses. However, the negative free cash flow growth rate is concerning, indicating increasing cash consumption without corresponding revenue growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	51.81M	63.52M	377.71M	60.92M	51.84M	24.00K
Gross Profit	-705.00K	63.52M	-59.67M	38.34M	35.40M	-103.16M
EBITDA	-419.86M	-383.98M	-156.47M	-324.33M	-392.46M	-128.03M
Net Income	-398.58M	-376.74M	-132.53M	-263.59M	-341.36M	-256.42M
Balance Sheet
Total Assets	1.39B	1.10B	1.46B	1.34B	1.47B	451.68M
Cash, Cash Equivalents and Short-Term Investments	1.15B	850.74M	1.19B	1.08B	965.65M	299.67M
Total Debt	154.80M	161.43M	172.69M	179.00M	142.35M	100.23M
Total Liabilities	344.34M	370.28M	478.38M	608.24M	647.72M	206.12M
Stockholders Equity	1.05B	733.54M	981.33M	733.47M	826.74M	245.56M
Cash Flow
Free Cash Flow	-355.57M	-356.19M	-182.93M	-26.42M	-113.08M	-112.10M
Operating Cash Flow	-344.82M	-347.25M	-149.19M	22.53M	-66.27M	-95.74M
Investing Cash Flow	-144.52M	185.01M	71.84M	-461.34M	-294.14M	-100.12M
Financing Cash Flow	479.19M	7.74M	276.45M	111.59M	756.14M	322.32M

Beam Therapeutics Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 17.62
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BEAM, the sentiment is Negative. The current price of 17.62 is below the 20-day moving average (MA) of 19.82, below the 50-day MA of 18.76, and below the 200-day MA of 22.51, indicating a bearish trend. The MACD of -0.43 indicates Positive momentum. The RSI at 35.50 is Neutral, neither overbought nor oversold. The STOCH value of 6.02 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BEAM.

Beam Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
PHAT	56 Neutral	$690.99M	―	181.41%	―	1049.81%	7.85%
NTLA	52 Neutral	$1.16B	―	-56.95%	―	14.99%	14.42%
Sector *	51 Neutral	$7.35B	-0.20	-44.62%	2.33%	29.35%	-1.02%
BEAM	50 Neutral	$1.78B	―	-41.94%	―	-82.90%	-155.64%
IMVT	45 Neutral	$2.64B	―	-77.58%	―	―	-48.38%
ETNB	42 Neutral	$1.34B	―	-86.86%	―	―	-82.75%

Beam Therapeutics Corporate Events

Beam Therapeutics Acquires Early-Stage Life Sciences Firm

On July 1, 2025, Beam Therapeutics Inc. acquired an early-stage life sciences company, agreeing to issue 403,128 shares of its common stock as an upfront payment and up to $89 million in additional milestone payments. This strategic acquisition is expected to enhance Beam’s capabilities and market position, potentially impacting its operations and stakeholders positively.

The most recent analyst rating on (BEAM) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Beam Therapeutics stock, see the BEAM Stock Forecast page.

Beam Therapeutics Confirms Key Decisions at Annual Meeting

On June 4, 2025, Beam Therapeutics held its annual meeting of stockholders, where key decisions were made regarding the company’s leadership and operations. The election of Class II directors, the ratification of Deloitte & Touche LLP as the independent auditor, and the approval of executive compensation were all confirmed, reflecting strong shareholder support and potentially impacting the company’s governance and financial oversight.

The most recent analyst rating on (BEAM) stock is a Hold with a $31.00 price target. To see the full list of analyst forecasts on Beam Therapeutics stock, see the BEAM Stock Forecast page.